Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases for $2.875 billion in cash
On Aug. 31, 2026, Eli Lilly and Merida Biosciences, a biotechnology company advancing a new class of precision…
On Aug. 31, 2026, Eli Lilly and Merida Biosciences, a biotechnology company advancing a new class of precision…